Beyond the Cure: Navigating Hepatocellular Risk and Surveillance after Hepatitis C Eradication in the Direct-acting Antiviral Era (IMAGE)
Caption
The advent of DAAs has dramatically impacted chronic HCV management, significantly reducing the risk of HCC development. However, in patients with cirrhosis who achieve HCV eradication, the risk of HCC remains high and exceeds the surveillance threshold, justifying lifetime HCC surveillance. For patients with pre-treatment stage 3 fibrosis, HCC surveillance after viral eradication remains a topic of debate. Tailored screening strategies that balance risk, cost, and benefit are essential for improving outcomes in this group. Further studies that carefully assess risk factors for HCC occurrence after HCV viral eradication are needed to optimize individualized surveillance approaches.
Credit
Ashwani K. Singal, Chencheng Xie
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC